Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BA1202 in Advanced Solid Tumors
NCT05909241Phase 1Recruiting
- Sponsor
- Boan Biotech
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BA1202 in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 2 more, sponsored by Boan Biotech. Primary endpoint: Incidence and severity of adverse events up to 2 years. Started Aug 2023; status: recruiting.
02
Drugs
BA1202
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT05909241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909241.